DNA copy number alterations are believed to play a major role in the development and progression of human neoplasms. Although most of these genomic imbalances have been associated with dysregulation of individual genes, their large-scale transcriptional consequences remain unclear. Pancreatic carcinomas frequently display gene copy number variation of entire chromosomes as well as of chromosomal subregions. These changes range from homozygous deletions to high-level amplifications and are believed to constitute key genetic alterations in the cellular transformation of this tumor type. To investigate the transcriptional consequences of the most drastic genomic changes, that is, genomic amplifications, and to analyse the genome-wide transcriptional effects of DNA copy number changes, we performed expression profiling of 29 pancreatic carcinoma cell lines and compared the results with matching genomic profiling data. We show that a strong association between DNA copy numbers and mRNA expression levels is present in pancreatic cancer, and demonstrate that as much as 60% of the genes within highly amplified genomic regions display associated overexpression. Consequently, we identified 67 recurrently overexpressed genes located in seven precisely mapped commonly amplified regions. The presented findings indicate that more than one putative target gene may be of importance in most pancreatic cancer amplicons.
DNA copy number alterations are believed to play a major role in the development and progression of human neoplasms. Although most of these genomic imbalances have been associated with dysregulation of individual genes, their large-scale transcriptional consequences remain unclear. Pancreatic carcinomas frequently display gene copy number variation of entire chromosomes as well as of chromosomal subregions. These changes range from homozygous deletions to high-level amplifications and are believed to constitute key genetic alterations in the cellular transformation of this tumor type. To investigate the transcriptional consequences of the most drastic genomic changes, that is, genomic amplifications, and to analyse the genome-wide transcriptional effects of DNA copy number changes, we performed expression profiling of 29 pancreatic carcinoma cell lines and compared the results with matching genomic profiling data. We show that a strong association between DNA copy numbers and mRNA expression levels is present in pancreatic cancer, and demonstrate that as much as 60% of the genes within highly amplified genomic regions display associated overexpression. Consequently, we identified 67 recurrently overexpressed genes located in seven precisely mapped commonly amplified regions. The presented findings indicate that more than one putative target gene may be of importance in most pancreatic cancer amplicons. Keywords: expression profiling; genomic profiling; microarray; pancreatic cancer A common feature in human malignancies is the presence of genomic imbalances. Even though some of these are tumor specific, the majority can be found in a large number of different tumor types (Mertens et al., 1997) . The consistent presence of these genomic alterations indicates that an apparently tumor-type independent selective advantage is added to the transformed cell, most probably through modified expression levels of genes in the affected segments. This is supported by studies of breast cancer, where parallel microarray analyses of mRNA (expression profiling) and DNA (genomic profiling) have shown a consistent association between gene copy numbers and expression levels (Hyman et al., 2002; Pollack et al., 2002) . These studies indicate that DNA copy number has a major impact on transcription, especially in high-level amplifications where as many as 44-62% of the affected genes also show overexpression. However, similar data from colon cancer indicate that only 4% of the amplified genes respond in terms of increased expression (Platzer et al., 2002) . In the present study, we set out to determine whether the strong gene dosage/expression correspondence is restricted to breast cancer, or reflects a more common phenomenon that also applies to other tumor types. Pancreatic carcinomas frequently show imbalances of entire chromosomes as well as of smaller genomic segments. The DNA copy number variations, which range from homozygous deletions to high-level amplifications, are believed to constitute key genetic alterations in the development and progression of this tumor type. To investigate the genome-wide transcriptional effects of gene copy number alterations, in particular of genomic amplifications, we performed expression profiling analyses of 29 pancreatic carcinoma cell lines using cDNA microarrays, and compared the results with matching genomic profiling data (Heidenblad et al., 2004) . The analysis of the combined genomic and expression data sets allowed us to (i) determine the genome-wide association between gene copy number and expression levels in pancreatic cancer, (ii) identify 67 recurrently overexpressed genes in seven precisely mapped commonly amplified regions, and (iii) analyse the genome-wide mRNA effects two of the most frequently amplified regions in pancreatic cancer, 8q23-24 and 12p11-12.
To evaluate the global transcriptional consequences of gene copy number alterations, paired gene expression and DNA copy number ratios from 10 of the cell lines were analysed. A total of 79 927 paired observations, representing 13 720 different cDNA clones, were included. Based on gene copy number ratios, these were subdivided into seven categories with fold-changes o0.7, 0.7-0.9, 0.9-1.1, 1.1-1.5, 1.5-2.0, 2.0-2.5, and >2.5. In Figure 1a , all expression levels within the respective categories are plotted. Gene copy fold-changes below 0.9, and between 1.1 and 2.0, corresponding to gains or losses of 1-2 gene copies, respectively, did not result in any major changes of the expression levels. However, when the fold-changes exceeded 2.0, a large effect was seen, both on the number of genes affected and on the maximum expression levels. This pattern was even more pronounced in the category with >2.5-fold DNA amplification.
To investigate specifically the relationship between gene copy numbers and proportion of over-/underexpressed genes, these were defined as the upper and lower 7th percentiles (Hyman et al., 2002) of the B80 000 expression measurements. The fraction of over-and underexpressed genes within each gene copy number category revealed that the former showed a strong positive association with DNA copy numbers, and that the latter showed a less pronounced negative association with the number of genomic copies present ( Figure 1b ). The category with gene copy fold-changes o0.7 showed over-and underexpression of 5.1 and 12%, respectively, of the genes in this group, whereas the equivalent fractions in the highest copy number category were 53 and 3.4%. In the normal copy number group (ratios 0.9-1.1), 6.2% of the genes were overexpressed and 6.5% underexpressed. To evaluate the effects of the most highly amplified genomic sequences in more detail, we raised the threshold ratio of the highest DNA copy number category to 3.0 and 3.5. This analysis showed that 62% of the genes in the former and 60% of the genes in the latter were overexpressed, suggesting that a maximum fraction of susceptible genes seems to be affected when fold-changes exceed 3.0, equivalent to approximately 10 gene copies in the present microarray platform. A consequence of these findings is that a change from a low-to a high-level amplification not only results in further upregulation of genes already overexpressed at low gene copy numbers but also in additional genes within a given segment becoming upregulated. Hence, the biological outcome of high-level amplifications may be very different from that of gains and low-level amplifications of the same segment. The maximum of 60% affected genes in highlevel amplifications is in agreement with observations in breast cancer using array-based comparative genomic hybridization (CGH) for amplicon mapping (Hyman et al., 2002; Pollack et al., 2002) , but differs substantially from findings in colon cancer based on traditional CGH for amplicon delineation (Platzer et al., 2002) . A partial explanation for this discrepancy could be that CGH analyses on metaphase chromosomes generally overestimate the size of amplified segments, potentially leading to analysis of a large number of unamplified genes, which in turn would reduce the frequency of affected genes.
We previously determined the exact genomic boundaries of 60 amplicons in the investigated cell lines (Heidenblad et al., 2004) . In total, 491 (36%) of the UniGene clusters harboring clones in these segments were found to show more than twofold increased expression (Supplementary Table 1 ). By using a criterion of more than twofold overexpression in at least two cases with genomic amplification, a final list of 67 < 0.7 0.7-0.9 0.9-1.1 1.1-1.5 1.5-2.0 2.0-2.5 > 2.5 Copy number ratio < 0.7 0.7-0.9 0.9-1.1 1.1-1.5 1.5-2.0 2.0-2.5 > 2.5
Copy number ratio Overexpressed Underexpressed Figure 1 Association between gene copy number and expression levels. To obtain a reliable and representative assembly of paired genomic and transcriptional observations for the association analysis, we used the following selection criteria. First, based on the genomic aberration spectra and hybridization qualities of both hybridizations, 10 tumor cell lines were selected; AsPC-1, DANG, HupT3, LPC3p, LPC4p, LPC5 m, LPC10 m, LPC11p, LPC13p, and LPC14p. Second, to enrich high-quality observations within this subset of tumor cell lines, we used a signal-to-noise filter of 3.0 for both dyes, and for both experiments. Only cDNA clones with at least one paired observation remaining after this filtration were included in the association analysis (a total of 13 720 of 25 468). In total, 79 927 paired ratios from the 10 cases were analysed. For detailed information on cell lines and hybridizations, see legends to 
Gene/EST Band Mb
Transcriptional patterns in pancreatic cancer M Heidenblad et al 1.9-fold upregulation in another (data not shown). The increase in SMURF1 expression is noteworthy in light of the frequent inactivation of the TGFB-signaling pathway in pancreatic carcinomas (Bardeesy and DePinho, 2002) . Among the 14 identified candidate genes in 8q24, the most frequently overexpressed were LOC286052 and LOC157378, upregulated more than twofold in three and four of the cases with this amplification, respectively (Figure 2 ). No molecular functions have been assigned to these genes. The MYC oncogene, amplified in seven cases, unexpectedly showed decreased expression in four of these and more than twofold overexpression in only one case. The microarray results for MYC were verified by RT-PCR (data not shown).
We previously identified BHLBH3 (DEC2), KRAS2 and PPFIBP1 as possible target genes for 12p amplifications in pancreatic carcinomas (Heidenblad et al., 2002) . In the present study, as many as 20 additional putative target genes/ESTs were identified in this region (Figure 2) , four of which (EKI1, BCAT, CMAS, and SURB7) have also been shown to be overexpressed in testicular germ cell tumors with similar amplifications (Rodriguez et al., 2003) . Both cases with 17q23 amplifications showed more than twofold upregulated expression of FLJ12760 and TLK2. No function has been assigned to FLJ12760, whereas TLK2 is a serine/ threonine kinase activated by cell cycle-dependent phosphorylation. Interestingly, both genes showed increased expression exclusively in cases with amplification, indicating a strong link between DNA copy number and gene expression (Figure 2 ). Amplification and overexpression of AKT2 in 19q13.2 is well established in pancreatic cancer (Cheng et al., 1996) . In the present investigation, we identified 12 additional amplified and overexpressed genes in this region, including PAK4 (Mahlama¨ki et al., 2004) , involved in the reorganization of the cytoskeleton and in inducing antiapoptotic effects. Thus, by systematically searching for overexpressed genes within precisely mapped amplicons in these cell lines, it became evident that several genes in each amplified segment showed significant transcriptional response to the corresponding copy number increase. Accordingly, in many of the amplified segments where established oncogenes have been identified, additional genes with possible tumorigenic effects are colocalized and overexpressed. This indicates that more than one gene may be of selective advantage in each commonly amplified region.
Apart from the amplified regions listed in Figure 2 , we identified 22 unique amplicons and three genomic segments that were recurrently amplified but did not show any commonly overexpressed genes as determined by the array analyses. Three of these regions were selected for more detailed analysis (Figure 3a-c) . The first, located to 6p21.1, was amplified in two cases, LPC3p and SU.86.86. As the commonly amplified segment contained CCND3, highly overexpressed in LPC3p (Figure 3a) but not in SU.86.86 as determined by the array study, RT-PCR analysis was performed. This confirmed the microarray results for LPC3p (Figure 3d ) and indicated a 2.2-fold increased expression in SU.86.86 (data not shown). The second region involved two unique 8p amplifications in DANG (Figure 3b ). As 8p is lost in approximately 60% of pancreatic carcinomas (Hahn et al., 1995) , and adverse genomic instability is frequent in this tumor type (Gorunova et al., 1998) , we hypothesized that these alterations could be biologically less significant side effects of the genomic instability. However, the expression profile of this case revealed five genes with highly increased expression (>4-fold) in the distal amplicon, and six genes with more than twofold overexpression in the proximal amplicon (Figure 3b and Supplementary  Table 1 ). Among these, at least BAG4, a member of the BAG1-related protein family that inhibits apoptosis, may contribute to cellular transformation. The Figure 2 List of putative amplification target genes. The figure shows 67 genes/ESTs identified as amplified and overexpressed more than twofold in at least two cases. Expression levels are shown for all 29 cases and are depicted on a log2-based pseudocolor scale (color code on top). Red and green squares indicate over-and underexpression, respectively, and gray areas denote missing values. Surrounding boxes in yellow show cases in which the respective genes are amplified. To the right, gene symbols, clone identities, and chromosomal localizations are given. In cases where genes are represented by more than one cDNA clone on the microarray, the mean expression of the clones listed is shown. For cDNA clones lacking gene symbol annotation, clone identities are shown with the corresponding UniGene cluster number. The 29 pancreatic carcinoma cell lines analysed comprised LPC1p, LPC2p, LPC3p, LPC4p, LPC5m, LPC6p, LPC7m, LPC8p, LPC10m, LPC11p, LPC12m, LPC13p, LPC14p, and LPC15p, which have been previously described (Jonson et al., 1999; Heidenblad et al., 2004) , and the established cell lines AsPC-1, BxPC-3, Capan-2, CFPAC-1, DANG, Hs700T, Hs766T, HupT3, HupT4, PANC-1, PaTu8902, PaTu8988S, PaTu8988T, SU.86.86, and SW1990 obtained from cell repositories. Expression profiling was performed using cDNA microarrays, containing 25 648 different cDNA clones (17,494 UniGene clusters) obtained from the Swegene DNA microarray resource center at Lund University (http://swegene.onk.lu.se). Amplified tumor cell line and reference RNA (RiboAmp RNA amplification kit, Arcturus, Mountain View, CA, USA) was differentially labeled (CyScribe Post Labeling kit, Amersham Biosciences, Uppsala, Sweden) with Cy3-and Cy5-dUTP, respectively. As reference, a pool containing equal amounts of all amplified RNA samples was used. Labeled cDNAs were hybridized to the microarrays for 18 h. Preand post-treatments of microarray slides were performed according to Universal Hybridization Kit manual (Corning, Acton, MA, USA). Fluorescence intensities were quantified on an Agilent G2565AA microarray scanner (Agilent technologies, Palo Alto, CA, USA) and the raw images were analysed using the GenePix Pro 4.0 software (Axon Instruments, Inc., Foster City, CA, USA). Background corrected data were Lowess normalized (smoothing factor 0.33) and filtered (signal-to-noise ratio >3.0) using the webbased database BASE (Saal et al., 2002) . For mapping and annotations of cDNA clones, data available through the UCSC genome browser (http://genome.ucsc.edu, July 2003 freeze) and NCBI (http://www.ncbi.nlm.nih.gov/UniGene, UniGene Build 164) were used. Genomic profiling information from the 29 cell lines was extracted from previously published data (Heidenblad et al., 2004) . The data sets are available at http://www.klingen.lu.se/E/research Transcriptional patterns in pancreatic cancer M Heidenblad et al overexpression of this gene was validated by RT-PCR (Figure 3d ). This suggests that small and infrequent amplifications may also harbor genes of potential importance for tumor development.
The third region, located at 20q13.2, was amplified in LPC3p (Figure 3c ) and PaTu8988T. Amplification of this segment is frequent in various malignancies, and in breast cancer, ZNF217 and CYP24A1 have been proposed as target genes (Albertson et al., 2000) . Even though both of these genes were located in the amplification maximum of LPC3p, ZNF217 showed no transcriptional response, and CYP24A1 showed considerable under-rather than overexpression (Figure 3c ). In contrast, PFDN4, also localized within the amplification, displayed a pronounced (>4-fold) overexpression (Figure 3c) . RT-PCR analysis of , and CYP24A1. For RT-PCR validations, including MET and MYC, two multiplex PCR reactions were performed for each gene, one including ACTB, and the other GAPD as internal standard. PCR conditions conformed to standard procedures, and quantification was performed by phosphorimaging as described previously (Heidenblad et al., 2002) . The expression levels were calculated as the mean of the ratios between the assayed genes and internal standards, normalized against the reference. As reference, a combination of cDNA samples from all 29 cases was used, equivalent to the reference applied in the expression profiling Figure 4 Gene expression signatures associated with amplifications of (a) 8q24 and (b) 12p11-12. The figure shows 98/71 genes/ESTs differentially expressed, as determined by a Bonferroni adjusted t-test (Po0.05) using the TIGR MeV suite of software (Saeed et al., 2003) , in cases with 8q24/12p11-12 amplifications as compared with their unaffected counterparts. The cases were selected based on previous conventional and array-based CGH data (Mahlama¨ki et al., 1997; Heidenblad et al., 2004) . Expression levels are presented on a log2-based pseudocolor scale (color code on top), where red and green indicate over-and underexpression, respectively, and gray denotes missing values. Genes included in the respective amplicons are enclosed in yellow boxes. To the right, gene symbols, clone identities, and chromosomal localizations according to the UCSC genome browser (July 2003 freeze) are given. In cases where genes are represented by more than one cDNA clone on the microarray, the mean expression of the clones listed is shown. (Figure 3d ). The expression patterns of all three genes in PaTu8988T were similar to the patterns seen in LPC3p, showing that even though the same genomic segments are amplified in different tumor types, their transcriptional outcome may vary. A limitation in the above used selection of amplification targets is that it does not take the dynamic expression range of the individual genes into consideration; genes showing less than twofold upregulation may also be of biological importance. Moreover, identified target genes may also be upregulated in cases with normal gene copy numbers. As an alternative strategy to identify genes more strongly associated with genomic amplifications, we used a t-test between cases with and without amplification. As the whole data set was used, genes at genomic locations other than the amplified ones, possibly affected by the amplifications, were also identified. The inclusion criterion of at least four cases per evaluated group limited the analyses to 8q23-24 and 12p11-12 in the present data set. The t-test identified one gene in the commonly amplified 8q region, FLJ14825 (Figure 4a ), a gene with unknown function that showed increased expression when amplified. Notably, this gene was not identified using the previous strategy. In addition, 97 genes in locations other than 8q showed significantly altered expression; 46 upregulated and 51 downregulated (Figure 4a ). The analysis of 12p identified six genes located within the commonly amplified region (Figure 4b ), all of which were also identified in the previous analysis. Moreover, 33 upregulated and 32 downregulated genes in other genomic locations were identified (Figure 4b ). Hence, these analyses not only complemented the previous strategy to identify putative target genes but also provided an opportunity to analyse potential indirect consequences of the 8q23-24 and 12p11-12 amplifications.
The presented data have shown that the standard approach to analyse genomic amplifications has several limitations. First, high-level amplifications are likely to affect a large number of genes. This, and the currently limited amount of functional data available for many genes, complicate the selection of primary putative target sets. Second, cases with normal copy numbers may also overexpress genes within commonly amplified regions, making the link between increased expression and amplification less significant. This means that elevated expression of an amplified gene cannot alone be considered as strong and sufficient evidence for being a candidate oncogene. Furthermore, the presented data point to an alternative interpretation of genomic amplifications, namely that the target may consist of several genes, and that the spectrum of affected genes may vary both among tumor cases and between different tumor types. Taken together, the dynamics of altered gene expression due to increased gene copies as well as the complex structure of amplicon profiles makes the identification of possible target genes based on amplicon mapping, patterns of altered gene expression, and gene annotations a delicate matter.
